IL103928A0 - Expression of specific immunogens using viral antigens - Google Patents

Expression of specific immunogens using viral antigens

Info

Publication number
IL103928A0
IL103928A0 IL103928A IL10392892A IL103928A0 IL 103928 A0 IL103928 A0 IL 103928A0 IL 103928 A IL103928 A IL 103928A IL 10392892 A IL10392892 A IL 10392892A IL 103928 A0 IL103928 A0 IL 103928A0
Authority
IL
Israel
Prior art keywords
expression
viral antigens
specific immunogens
immunogens
specific
Prior art date
Application number
IL103928A
Other languages
English (en)
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of IL103928A0 publication Critical patent/IL103928A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL103928A 1991-12-11 1992-11-30 Expression of specific immunogens using viral antigens IL103928A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80510591A 1991-12-11 1991-12-11

Publications (1)

Publication Number Publication Date
IL103928A0 true IL103928A0 (en) 1993-04-04

Family

ID=25190685

Family Applications (1)

Application Number Title Priority Date Filing Date
IL103928A IL103928A0 (en) 1991-12-11 1992-11-30 Expression of specific immunogens using viral antigens

Country Status (17)

Country Link
US (1) US5591823A (enExample)
EP (1) EP0546787A3 (enExample)
JP (1) JPH05262667A (enExample)
KR (1) KR930013112A (enExample)
CN (1) CN1073878A (enExample)
AU (1) AU2981992A (enExample)
BR (1) BR9204978A (enExample)
CA (1) CA2084180A1 (enExample)
CZ (1) CZ362692A3 (enExample)
FI (1) FI925590A7 (enExample)
HU (2) HUT65366A (enExample)
IL (1) IL103928A0 (enExample)
MX (1) MX9207113A (enExample)
NO (1) NO924780L (enExample)
SK (1) SK362692A3 (enExample)
TW (1) TW239162B (enExample)
ZA (1) ZA929355B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT633929E (pt) * 1992-04-01 2004-07-30 Merix Bioscience Inc Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios
EP0671926B1 (en) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
WO1995007099A1 (en) * 1993-09-09 1995-03-16 The Nisshin Oil Mills, Ltd. Vaccine and process for producing the same
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
EP2374894B1 (en) * 1993-09-13 2014-09-17 Protein Sciences Corporation A method for producing influenza hemagglutinin multivalent vaccines
ES2370937T3 (es) 1993-09-13 2011-12-23 Protein Sciences Corporation Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
PT1275726E (pt) * 1995-05-26 2008-05-16 Protein Sciences Corp Método para produzir vacinas multivalentes de hemaglutinina de influenza
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
WO1998048834A1 (en) * 1997-04-30 1998-11-05 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
ATE428769T1 (de) 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
WO1999042564A2 (en) 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
WO2002026252A1 (en) * 2000-08-10 2002-04-04 Tsinghua University A vaccine for influenza virus and its preparation
BR0114126A (pt) 2000-09-11 2003-08-26 Dow Global Technologies Inc Reforço de pneu para rodar vazio e método de fabricação
WO2004091491A2 (en) * 2003-04-10 2004-10-28 Transform Pharmaceuticals, Inc. Profiling conformational variants, antibody compositions and methods of using the same
KR20080027777A (ko) * 2005-06-01 2008-03-28 배리에이션 바이오테크놀로지스 아이엔씨. 펩티드­기초 인플루엔자 백신 제제
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
TWI494319B (zh) * 2007-02-21 2015-08-01 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
CA2697373C (en) * 2007-08-27 2019-05-21 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
MX2011004176A (es) 2008-10-22 2011-09-21 Oncotherapy Science Inc Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo.
CN101708442B (zh) * 2009-09-04 2011-08-24 山东中惠仪器有限公司 全自动标准气体配制装置
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
SG10202108573TA (en) * 2016-02-03 2021-09-29 Cg Discovery Inc Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites
US10063211B2 (en) 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
EP0492920A1 (en) * 1990-12-24 1992-07-01 Merck & Co. Inc. Chimaeric influenza-HIV vaccine

Also Published As

Publication number Publication date
KR930013112A (ko) 1993-07-21
JPH05262667A (ja) 1993-10-12
FI925590L (fi) 1993-06-12
EP0546787A2 (en) 1993-06-16
CZ362692A3 (en) 1994-02-16
SK362692A3 (en) 1995-11-08
CN1073878A (zh) 1993-07-07
BR9204978A (pt) 1993-06-15
HUT65366A (en) 1994-05-02
TW239162B (enExample) 1995-01-21
HU9203931D0 (en) 1993-04-28
NO924780D0 (no) 1992-12-10
AU2981992A (en) 1993-06-17
FI925590A0 (fi) 1992-12-09
NO924780L (no) 1993-06-14
ZA929355B (en) 1994-06-02
MX9207113A (es) 1994-05-31
US5591823A (en) 1997-01-07
HU211548A9 (en) 1995-12-28
CA2084180A1 (en) 1993-06-12
EP0546787A3 (en) 1994-06-01
FI925590A7 (fi) 1993-06-12

Similar Documents

Publication Publication Date Title
EP0546787A3 (en) Expression of specific immunogens using viral antigens
PL324906A1 (en) Vaccines against viral hepatitis of c type
PL321966A1 (en) Vaccine against viral hepatitis of b type
GB8907914D0 (en) Vaccine preparation
ZA922011B (en) Vaccine
EP0391997A4 (en) Vaccine
NZ215155A (en) Immunogens and compounds containing antigens and/or antigenic determinants
LTIP335A (en) Vaccine for human immunodeficiency virus
GB8704647D0 (en) Vaccine
HUT65487A (en) Vaccine containing modified herpesvirus
GB9020683D0 (en) Isolation of dna
OA09636A (en) Vaccine
ZA94740B (en) Expression of pretective antigens
ZA917307B (en) Process for the preparation of aminopyrimidines
GB9020799D0 (en) Viral vaccines
GB9104903D0 (en) Viral vaccines
GB8622883D0 (en) Expression of hepatitis b viral antigens
GB9122301D0 (en) Novel antigens
GB9117602D0 (en) Novel antigens
HU907120D0 (en) In-vitro mass microproliferation of lilies by means of histogenesis
GB8621578D0 (en) Hepatitis b viral antigens
GB8821078D0 (en) Improvements relating to antigens
ZA891686B (en) Improvements relating to antigens
GB9211317D0 (en) Novel antigens
ZA916490B (en) Footrot vaccine